Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China-based Yabao Pharmaceutical and Lawson Health Research Institute (Lawson) have completed the discovery validation work of products based on annexin A5 and moved the program into preclinical development.
Subscribe to our email newsletter
The companies entered into an exclusive license in July 2014 to discover, develop and commercialize these products for the treatment of sepsis.
Yabao Pharmaceutical R&D president Dr Peng Wang said: "Yabao is pleased to collaborate with Lawson, a leading Canadian research institute focused on improving the lives of patients through medical discovery.
"Yabao is also very pleased that the program has been moving very smoothly, showing great potential as a novel drug candidate for a huge unmet medical need.
"This opportunity for Yabao to further develop leading research into innovative products is further evidence of Yabao’s growing commitment to partner the best science to treat serious diseases in China."
A team led by Lawson and Western University scientist Dr Qingping Feng discovered the use of annexin A5 to treat sepsis.
As part of the deal, Yabao receives exclusive rights to discover, develop and commercialize in China, Taiwan and Hong Kong, while Lawson retains rights in all other markets.